Nox4 as a potential therapeutic target for treatment of uremic toxicity associated to chronic kidney disease

Kidney International

Volumn 83, Issue 4, 2013, Pages 541-543

  Gorin, Yves ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CRESYL SULFATE; ADVANCED GLYCATION END PRODUCT; ANTISENSE OLIGONUCLEOTIDE; FLAVINE ADENINE NUCLEOTIDE; HOMOCYSTEINE; HYDROGEN PEROXIDE; INDICAN; PARA CRESOL; PROTEIN INHIBITOR; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG; UREMIC TOXIN;

ARTICLE; CELL DAMAGE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; KIDNEY TUBULE CELL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UREMIA;

EID: 84875760398     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.434     Document Type: Note

References (10)

1. Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatr Nephrol 2008; 23: 1211-1221.
2. Niwa T. Indoxyl sulfate is a nephrovascular toxin. J Ren Nutr 2010; 20(Suppl): S2-S6.
3. Vanholder R, Bammens B, de Loor H et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26: 1464-1467.
4. Liabeuf S, Barreto DV, Barreto FC et al. European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191.
5. Watanabe H, Miyamoto Y, Honda D et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress through the activation of NADPH oxidase. Kidney Int 2013; 83: 582-592.
6. Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 2011; 79: 944-956.
7. Lassègue B, San Mart́n A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012; 110: 1364-1390.
8. Sedeek M, Gutsol A, Montezano AC et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 2013; 124: 191-202.
9. Jiang JX, Chen X, Serizawa N et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012; 53: 289-296.
10. Laleu B, Gaggini F, Orchard M et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010; 53: 7715-7730.